Kala Pharmaceuticals Stock Today

KALA Stock  USD 6.64  0.20  2.92%   

Performance

Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
Kala Pharmaceuticals is trading at 6.64 as of the 23rd of February 2025, a 2.92 percent decrease since the beginning of the trading day. The stock's open price was 6.84. Kala Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 24th of January 2025 and ending today, the 23rd of February 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
20th of July 2017
Category
Healthcare
Classification
Health Care
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. Kala Pharmaceuticals, Inc. The company has 6.09 M outstanding shares of which 159.3 K shares are now shorted by private and institutional investors with about 2.32 trading days to cover. More on Kala Pharmaceuticals

Moving against Kala Stock

  0.66VINC Vincerx PharmaPairCorr
  0.62VKTX Viking Therapeutics Buyout TrendPairCorr
  0.58DSGN Design TherapeuticsPairCorr
  0.45VANI Vivani MedicalPairCorr
  0.45VERA Vera TherapeuticsPairCorr
  0.44DRRX DurectPairCorr

Kala Stock Highlights

ESG Sustainability
60.7%
Environmental
65.8%
Governance
69.0%
Social
ChairmanMark Iwicki
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
2 Opinions
Strong Buy50%Buy50%100%
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.0280.0403
Way Down
Slightly volatile
Gross Profit Margin0.590.39
Way Up
Slightly volatile
Total Current Liabilities18 M9.6 M
Way Up
Slightly volatile
Non Current Liabilities Total59.2 M36.1 M
Way Up
Very volatile
Total Assets116.8 M64.3 M
Way Up
Slightly volatile
Total Current Assets98.6 M60.8 M
Way Up
Slightly volatile
Debt Levels
Kala Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kala Pharmaceuticals' financial leverage. It provides some insight into what part of Kala Pharmaceuticals' total assets is financed by creditors.
100%
Total Current Assets77.8%Net Tangible Assets16.88%Non...O...O...N...100%
Liquidity
Kala Pharmaceuticals currently holds 36.32 M in liabilities with Debt to Equity (D/E) ratio of 4.77, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kala Pharmaceuticals has a current ratio of 2.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Kala Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Sale Purchase Of Stock

398,762
67.9M97.1M71.3M9.0M160.7M1.6M365.0K419.8K398.8K100%
Kala Pharmaceuticals (KALA) is traded on NASDAQ Exchange in USA. It is located in 1167 Massachusetts Avenue, Arlington, MA, United States, 02476 and employs 43 people. Kala Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.45 M. Kala Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 6.09 M outstanding shares of which 159.3 K shares are now shorted by private and institutional investors with about 2.32 trading days to cover. Kala Pharmaceuticals currently holds about 44.57 M in cash with (27.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 30.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Kala Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Kala Pharmaceuticals is $40.45 Million. Over half of Kala Pharmaceuticals' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Institutions58.58%Public37.3%I...100%
Check Kala Ownership Details

Kala Stock Institutional Holders

InstituionRecorded OnShares
Two Sigma Investments Llc2024-09-30
14 K
Morgan Stanley - Brokerage Accounts2024-09-30
995
Covestor Ltd2024-09-30
969
Tower Research Capital Llc2024-09-30
754
Compagnie Lombard, Odier Sca2024-12-31
400
Citigroup Inc2024-09-30
296
Cwm, Llc Duplicate2024-12-31
200
Steward Partners Investment Advisory, Llc2024-12-31
120
Advisor Group Holdings, Inc.2024-12-31
100.0
Baker Bros Advisors Lp2024-12-31
1.2 M
Sr One Capital Management, Lp2024-12-31
598.9 K
View Kala Pharmaceuticals Diagnostics

Kala Pharmaceuticals Historical Income Statement

At present, Kala Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Research Development is expected to grow to about 21.9 M, whereas Interest Expense is forecasted to decline to about 4.9 M. View More Fundamentals

Kala Stock Against Markets

Kala Pharmaceuticals Corporate Management

CPA CPACFO TreasurerProfile
Jill SteierExecutive CommunicationsProfile
Carl RennieExecutive ManagementProfile
MBA JDChief OfficerProfile
Kim BrazzellChief Medical OfficerProfile
When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.67)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.44)
Return On Equity
(4.31)
The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.